SCHEMBL22679489

SCHEMBL22679489

Cc1nccc2c1NCCN2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.42
ADRA2B P18089 2/20 0.42
ADRA2C P18825 2/20 0.42
ADRA1D P25100 2/20 0.42
ADRA1A P35348 2/20 0.42
ADRA1B P35368 2/20 0.42
CYP2A6 P11509 1/20 0.33
PDE3B Q13370 2/20 0.32
PDE3A Q14432 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
GABRA1 P14867 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23257888 0.78 PDE3B (0.38) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL23328080 0.74 ADRA2A (0.33) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL18510121 0.72 NOTUM (0.42) BRD4
SCHEMBL23508937 0.72 CHRNB2 (0.35) CYP2A6PDE3BPDE3AKDM4EMEN1
SCHEMBL19153713 0.69 SRC (0.37) CYP2A6KDM4EALDH1A1MAPTHPGD
SCHEMBL19153130 0.69 UHRF1 (0.41) KDM4EALDH1A1MAPTHSD17B10NOS3
SCHEMBL24753233 0.68 ALDH1A1 (0.43) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL19657537 0.67 CREBBP (0.40) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL8090872 0.67 ADRA2A (0.47) ADRA2AADRA2BADRA2CADRA1DADRA1A
SCHEMBL31357070 0.67 CREBBP (0.40) ADRA2AADRA2BADRA2CADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020232256-A1 TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2020-11-19 WO disclosed